New research on VASCEPA impact for diabetes patients in September 2024

Amarin Corporation plc has announced significant new research regarding the clinical effects of VASCEPA (icosapent ethyl) on patients with diabetes and high cardiovascular risk. This research is particularly relevant given the increased mortality risk associated with elevated lipoprotein(a) levels in these patients. The findings will be showcased at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting, taking place in Madrid from September 9 to 13, 2024. The research includes a post-hoc analysis from the REDUCE-IT trial, which examines the effects of VASCEPA on a specific subgroup of patients who have both established cardiovascular disease and diabetes mellitus. Additionally, an in-vitro analysis will explore the effects of eicosapentaenoic acid (EPA) on lipoprotein(a) oxidation under conditions that mimic hyperglycemia. The implications of this research are significant, as patients with diabetes and cardiovascular disease are at a heightened risk for future cardiovascular events. The findings could provide valuable insights into how VASCEPA may help mitigate these risks, particularly in patients with a history of coronary artery bypass grafting surgery. Overall, this research underscores the critical need for effective treatments targeting cardiovascular risks in diabetes patients, potentially leading to improved health outcomes and reduced mortality rates in this vulnerable population.